ARCHIVES

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

NCI director apologizes to cancer centers for inaction on working group report.

October 31, 2003

NCI Objections Delay GAO Report On Cancer Control

March 7, 1980

Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response

November 29, 2013

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

Cancer Panel Urges Improved Funding For Basic Science

June 16, 1995

Phase III Five-Year Data Show Erbitux Increases Survival Of Head And Neck Cancer

September 26, 2008